A new once-daily therapy for the symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence is now available in the UK.

Mirabegron (Betmiga) is the first in a new class of overactive bladder (OAB) treatment for over 30 years, offering healthcare professionals an alternative option to antimuscarinics, the standard treatment of care.

It works by stimulating the β3 receptors in the detrusor muscle of the bladder causing relaxation of the bladder muscle during the storage phase of the micturition cycle. This improves the storage capacity of the bladder without inhibiting bladder voiding, whereas antimuscarinics work by binding to muscarinic receptors in the bladder and inhibiting involuntary bladder contractions.

The availability of a new class of OAB treatment is important because of low adherence with antimuscarinics. Around half of patients discontinue antimuscarinic treatment after only three months, often due to lack of efficacy or intolerable side effects.

Professor Chris Chapple, Consultant Urological Surgeon at Sheffield Teaching Hospitals, said: "The introduction and availability of mirabegron in the treatment of OAB symptoms offers a new way of treating adult patients, providing an alternative treatment option without one of the most bothersome side effects of antimuscarinics."